Matches in Wikidata for { <http://www.wikidata.org/entity/Q66346440> ?p ?o ?g. }
Showing items 1 to 42 of
42
with 100 items per page.
- Q66346440 description "clinical trial" @default.
- Q66346440 description "ensayu clínicu" @default.
- Q66346440 description "klinisch onderzoek" @default.
- Q66346440 description "клінічне випробування" @default.
- Q66346440 description "կլինիկական փորձարկում" @default.
- Q66346440 name "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmon" @default.
- Q66346440 name "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol" @default.
- Q66346440 type Item @default.
- Q66346440 label "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmon" @default.
- Q66346440 label "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol" @default.
- Q66346440 prefLabel "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmon" @default.
- Q66346440 prefLabel "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol" @default.
- Q66346440 P1132 Q66346440-EF42561E-B5C8-4946-AC57-2BE15C0BA5D0 @default.
- Q66346440 P1476 Q66346440-99CBF905-B90E-42D1-8EB2-5B4763DA1C2D @default.
- Q66346440 P17 Q66346440-2F8D6D08-03E2-42FF-990B-0285142182A5 @default.
- Q66346440 P17 Q66346440-B78A73A8-BDE4-482C-B6E8-F45B6349B9E8 @default.
- Q66346440 P17 Q66346440-BE4CBC94-DDDD-43F6-A1F5-7D44A8DC5ABC @default.
- Q66346440 P17 Q66346440-F0E3B9E8-8DC7-43FC-B7D8-DA5F14CCECF3 @default.
- Q66346440 P2899 Q66346440-236E5594-E62E-45FE-A7A2-266AD8AB1EA6 @default.
- Q66346440 P3098 Q66346440-DB0CD6EC-83F3-41B3-B299-7F248BE790BD @default.
- Q66346440 P31 Q66346440-00A903D2-4A22-4C5F-90EA-0F37D22A417C @default.
- Q66346440 P4844 Q66346440-692DA2EF-9D32-496A-893E-9A0F98DEFF61 @default.
- Q66346440 P580 Q66346440-576720B2-4BE1-4B32-8089-3CFE57E0670D @default.
- Q66346440 P582 Q66346440-6A2FECBF-4BE2-4FB9-8029-0A2DECF8D8BF @default.
- Q66346440 P6099 Q66346440-57646DA4-1322-48EB-BCA8-2F4F54F9779F @default.
- Q66346440 P8363 Q66346440-AE1ECC6A-0799-46AB-A7C8-E7E07FC41296 @default.
- Q66346440 P859 Q66346440-97EC9481-9ED6-4943-9270-57F95BD6DE09 @default.
- Q66346440 P1132 "+828" @default.
- Q66346440 P1476 "A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)" @default.
- Q66346440 P17 Q183 @default.
- Q66346440 P17 Q212 @default.
- Q66346440 P17 Q218 @default.
- Q66346440 P17 Q30 @default.
- Q66346440 P2899 "+40" @default.
- Q66346440 P3098 "NCT01706328" @default.
- Q66346440 P31 Q30612 @default.
- Q66346440 P4844 Q27264747 @default.
- Q66346440 P580 "2012-10-15T00:00:00Z" @default.
- Q66346440 P582 "2013-06-17T00:00:00Z" @default.
- Q66346440 P6099 Q42824827 @default.
- Q66346440 P8363 Q78089383 @default.
- Q66346440 P859 Q212322 @default.